Phillip James Consulting »

Alnylam Pharmaceuticals shares owned by Phillip James Consulting

Quarter-by-quarter ownership of Alnylam Pharmaceuticals (ALNY) shares owned by Phillip James Consulting from 13F filings

Historical chart of Phillip James Consulting investment in Alnylam Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Alnylam Pharmaceuticals held by Phillip James Consulting consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alnylam Pharmaceuticals by Phillip James Consulting

Quarter filed Position value Share count Share price at filing
2026-03-31 $999 3 333.33

More positions owned by Phillip James Consulting

Schwab Short-term Us Treasury Etf Etf
Vanguard Short-term Bond Etf Etf (BND)
Schwab Us Broad Market Etf Etf
Ishares Msci Eafe Value Etf Etf
Schwab Us Large-cap Value Etf Etf
Vanguard Ftse All-world Ex-us Small-cap Etf Etf
Vanguard Small-cap Etf Etf
Schwab Intl Equity Etf Etf
Vanguard Small-cap Value Etf Etf
Vanguard Total Stock Market Etf Etf (VTI)
Schwab Us Small-cap Etf Etf
Spdr Portfolio Sp 500 Momentum Etf Etf (SHM)
Wisdomtree Intl Smallcap Dividend Fund Etf (DWM)
Vanguard Value Etf Etf
Spdr Portfolio Emerging Markets Etf Etf (SPHY)

View all positions for Phillip James Consulting

Top funds holding Alnylam Pharmaceuticals

FMR
Vanguard Group
Capital World Investors
BlackRock
Capital Research Global Investors
Vanguard Portfolio Management
Vanguard Capital Management
State Street Corporation
Geode Capital Management
Baillie Gifford & Co
Two Sigma Investments
Dodge & Cox
T. Rowe Price Investment Management
Wellington Management Company
American Century Companies

View all funds holding Alnylam Pharmaceuticals